Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features-Reference-Cited by-同舟云学术

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features

Published:2024-08-27 Issue: Volume: Page:
ISSN:2211-3428
Container-title:Cellular Oncology
language:en
Short-container-title:Cell Oncol.

Author:

Sierro-Martínez Belén,Escamilla-Gómez Virginia,Pérez-Ortega Laura,Guijarro-Albaladejo Beatriz,Hernández-Díaz Paola,de la Rosa-Garrido María,Lara-Chica Maribel,Rodríguez-Gil Alfonso,Reguera-Ortega Juan Luis,Sanoja-Flores Luzalba,Arribas-Arribas Blanca,Montiel-Aguilera Miguel Ángel,Carmona Gloria,Robles Maria Jose,Caballero-Velázquez Teresa,Briones Javier,Einsele Hermann,Hudecek Michael,Pérez-Simón Jose Antonio^ORCID,García-Guerrero Estefanía^ORCID

Funder

Instituto de Salud Carlos III

Consejeria de Salud y Familias, Junta de Andalucia

Consejeria de Universidad, Investigacion e Innovacion, Junta de Andalucia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13402-024-00984-0.pdf

Reference65 articles.

1. N.C. Munshi, L.D. Anderson, N. Shah, D. Madduri, J. Berdeja, S. Lonial et al., Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384(8), 705–716 (2021)

2. T. Martin, S.Z. Usmani, J.G. Berdeja, M. Agha, A.D. Cohen, P. Hari et al., Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. (2022)

3. J.G. Berdeja, D. Madduri, S.Z. Usmani, A. Jakubowiak, M. Agha, A.D. Cohen et al., Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 398(10297), 314–324 (2021)

4. B. Dhakal, K. Yong, S.J. Harrison, M.V. Mateos, P. van de Moreau et al., First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. 41(17_suppl), LBA106–LBA106 (2023). https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA106

5. J. San-Miguel, B. Dhakal, K. Yong, A. Spencer, S. Anguille, M.V. Mateos et al., Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. (2023). https://doi.org/10.1056/NEJMoa2303379